✦ LIBER ✦

Eliglustat, an Investigational Oral Therapy for Gaucher Disease Type 1 (GD1): Updated Phase 2 Results

✍ Scribed by M. Judith Peterschmitt; Elena Lukina; Nora Watman; Marta Dragosky; Marcelo Iastrebner; Gregory Pastores; Elsa Avila Arreguin; Mici Phillips; Hanna Rosenbaum; Elena Sysoeva; Rasha Aguzzi; Leorah Ross; Ana Cristina Puga

Book ID: 116989618
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 55 KB
Volume: 105
Category: Article
ISSN: 1096-7192
DOI: 10.1016/j.ymgme.2011.11.132

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Eliglustat, an investigational oral ther

Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4years of treatment

✍ Lukina, Elena; Watman, Nora; Dragosky, Marta; Pastores, Gregory M.; Arreguin, El 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 366 KB

Biomarker responses to eliglustat, an in

Biomarker responses to eliglustat, an investigational oral substrate reduction therapy (SRT) for Gaucher disease type 1 (GD1)

✍ Peterschmitt, M. Judith; Lukina, Elena; Watman, Nora; Dragosky, Marta; Pastores, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Eliglustat, an investigational oral ther

Eliglustat, an investigational oral therapy for gaucher disease type 1 (GD1): Phase 2 results and assessment of patient responses and achievement of established therapeutic goals after 2 years of treatment

✍ Ana Cristina Puga; Elena Lukina; Nora Watman; Marta Dragosky; Marcelo Lastrebner 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Eliglustat, an investigational oral ther

Eliglustat, an investigational oral therapy for Gaucher disease type 1 (GD1): Phase 2 results and assessment of patient responses and achievement of established therapeutic goals after 2 years of treatment

✍ Marta Dragosky; Elena Lukina; Nora Watman; Gregory Pastores; Marcelo Iastrebner; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 70 KB

Eliglustat for Gaucher disease Type 1 (G

Eliglustat for Gaucher disease Type 1 (GD1): Safety results from a Phase 2 study after 2 years of treatment

✍ M. Judith Peterschmitt; Elena Lukina; Nora Watman; Marta Dragosky; Marcelo Iastr 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 58 KB

102. Genz-112638, an investigational ora

102. Genz-112638, an investigational oral treatment for Gaucher disease type 1: Preliminary Phase 2 clinical trial results

✍ Judith Peterschmitt; Elena Lukina; Nora Watman; Elsa Arreguin; Maryam Banikazemi 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 43 KB